RUSSIA TO SUPPLY INDIA FIRM WITH 100M DOSES OF SPUTNIK V
THE Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and Dr. Reddy’s Laboratories Ltd. (Dr. Reddy’s), a global pharmaceutical company based in India, have agreed to cooperate on clinical trials and distribution of the Sputnik V vaccine in India.
Upon regulatory approval in India, RDIF shall supply to Dr. Reddy’s 100 million doses of the vaccine.
The Sputnik V vaccine, which is based on a well-studied human adenoviral vector platform with proven safety, is undergoing phase three clinical trials for the coronavirus pandemic.
Deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India.
The RDIF is also in talks with some manufacturers in India for the possible manufacture of the vaccine there.
The agreement between RDIF and Dr. Reddy’s reflects the growing awareness of countries and organizations to have a diversified anti-COVID vaccine portfolio to protect their populations.
“We are very pleased to partner with Dr.Reddy’s in India. Dr. Reddy’s has had a very well established and respected presence in Russia for over 25 years and is one of the leading pharmaceutical companies in India,” said RDIF chief executive officer Kirill Dmitriev.